Download PDF
CC BY-NC-ND 4.0 · Exp Clin Endocrinol Diabetes 2023; 131(11): 583-588
DOI: 10.1055/a-2145-1004
Article

Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD

Lin Liu‡   *
1   Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China
2   Fudan Institute for Metabolic Disease, Fudan University, Shanghai, China
,
Ruwen Wang‡   *
3   School of Kinesiology, Shanghai University of Sport, Shanghai, China
,
Jian Gao‡   *
4   Department of Nutrition, Zhongshan Hospital, Fudan University
5   Center of Clinical Epidemiology and Evidence-based Medicine, Fudan University
,
Jianhua Yan
6   Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China
,
Jingtian Zhang
4   Department of Nutrition, Zhongshan Hospital, Fudan University
,
Zhitian Zhang
1   Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China
,
Jiaojiao Liu
1   Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China
,
Huandong Lin
1   Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China
2   Fudan Institute for Metabolic Disease, Fudan University, Shanghai, China
,
Shengxiang Rao
7   Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China
,
Xiuzhong Yao
7   Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China
,
Weiyun Wu
8   Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
,
Hua Bian
1   Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China
2   Fudan Institute for Metabolic Disease, Fudan University, Shanghai, China
,
Xiangyu Wang
4   Department of Nutrition, Zhongshan Hospital, Fudan University
,
Shanshan Guo
3   School of Kinesiology, Shanghai University of Sport, Shanghai, China
9   School of Life Sciences, Fudan University, Shanghai, China
,
Xin Gao
1   Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China
2   Fudan Institute for Metabolic Disease, Fudan University, Shanghai, China
,
Hongmei Yan
1   Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China
2   Fudan Institute for Metabolic Disease, Fudan University, Shanghai, China
10   Department of Endocrinology and Metabolism, Wusong Branch of Zhongshan Hospital, Fudan University, Shanghai, China.
› Author Affiliations Funding Information Medical Guidance Project of Shanghai Science and Technology Commission — 19401931100 to Wang XY; Science and Technology Commission of Shanghai Municipality — http://dx.doi. org/10.13039/501100003399; 21ZR1413200 to HM Yan; Scientific Research and Development Foundation of Zhongshan Hospital, Fudan University — 2019ZSFZ10 to HD LIN
› Further Information
Also available at
   Permissions and Reprints

Abstract

Aim This study investigated the effects of insulin glargine and exenatide on the muscle mass of patients with newly diagnosed type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).

Methods We performed a post-hoc analysis of our previously study, a 24-week randomized controlled multicenter clinical trial (ClinicalTrials.gov, NCT02303730). Seventy-six patients were randomly assigned 1:1 to receive insulin glargine or exenatide treatment. The changes in psoas muscle area (PMA) (mm2) were obtained with the cross-sectional Dixonfat magnetic resonance images at the fourth lumber vertebra.

Results There were no significant differences in age, BMI, gender, and PMA in insulin glargine and exenatide groups at baseline. After treatment, PMA tended to increase by 13.13 (–215.52, 280.80) mm2 in the insulin glargine group and decrease by 149.09 (322.90–56.39) mm2 in the exenatide group (both p>0.05). Subgroup analysis showed a 560.64 (77.88, 1043.40) (mm2) increase of PMA in the insulin group relative to the Exenatide group in patients with BMI<28 kg/m2 (p0.031) after adjusting for gender, age, and research center. Interaction analysis showed an interaction between BMI and treatment (p0.009). However, no interaction was observed among subgroups with a BMI≥28 kg/m2 or with different genders and ages.

Conclusion Compared to exenatide, insulin glargine can relativity increase PMA in patients with T2DM having BMI<28 kg/m2 and NAFLD.

Key words

body composition - basal insulin - exenatide - fatty liver disease - type 2 diabetes - clinical trial

* These authors contributed equally: Lin Liu, Ruwen Wang, Jian Gao




Publication History

Received: 08 December 2022
Received: 27 June 2023

Accepted: 28 June 2023

Accepted Manuscript online:
31 July 2023

Article published online:
04 October 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Li Y, Teng D, Shi X. et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: National cross sectional study. BMJ (Clinical research ed) 2020; 369: m997
    CrossrefPubMedSearch in Google Scholar
  • 2 Salomon JA, Wang H, Freeman MK. et al. Healthy life expectancy for 187 countries, 1990-2010: A systematic analysis for the Global Burden Disease Study 2010. Lancet 2012; 380: 2144-2162
    CrossrefPubMedSearch in Google Scholar
  • 3 Dunning T, Sinclair A, Colagiuri S. New IDF Guideline for managing type 2 diabetes in older people. Diabetes Res Clin Pract 2014; 103: 538-540
    CrossrefPubMedSearch in Google Scholar
  • 4 Cho NH, Shaw JE, Karuranga S. et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018; 138: 271-281
    CrossrefPubMedSearch in Google Scholar
  • 5 Izzo A, Massimino E, Riccardi G. et al. A narrative review on sarcopenia in type 2 diabetes mellitus: Prevalence and associated factors. Nutrients 2021; 13
    CrossrefPubMedSearch in Google Scholar
  • 6 Cruz-Jentoft AJ, Bahat G, Bauer J. et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age and Ageing 2019; 48: 16-31
    CrossrefPubMedSearch in Google Scholar
  • 7 Delbono O, Rodrigues ACZ, Bonilla HJ. et al. The emerging role of the sympathetic nervous system in skeletal muscle motor innervation and sarcopenia. Ageing Res Rev 2021; 67: 101305
    CrossrefPubMedSearch in Google Scholar
  • 8 Shafiee G, Keshtkar A, Soltani A. et al. Prevalence of sarcopenia in the world: A systematic review and meta- analysis of general population studies. J Diabetes Metab Disord 2017; 16: 21
    CrossrefPubMedSearch in Google Scholar
  • 9 Papadopoulou SK. Sarcopenia: A contemporary health problem among older adult populations. Nutrients 2020; 12
    CrossrefPubMedSearch in Google Scholar
  • 10 Ida S, Nakai M, Ito S. et al. Association between sarcopenia and mild cognitive impairment using the Japanese version of the SARC-F in elderly patients with diabetes. J Am Med Dir Assoc 2017; 18: 809.e809-809.e813
    CrossrefPubMedSearch in Google Scholar
  • 11 Cruz-Jentoft AJ, Landi F, Schneider SM. et al. Prevalence of and interventions for sarcopenia in ageing adults: A systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 2014; 43: 748-759
    CrossrefPubMedSearch in Google Scholar
  • 12 Wang T, Feng X, Zhou J. et al. Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre-sarcopenia in Chinese elderly. Sci Rep 2016; 6: 38937
    CrossrefPubMedSearch in Google Scholar
  • 13 Cobo A, Vázquez LA, Reviriego J. et al. Impact of frailty in older patients with diabetes mellitus: An overview. Endocrinologia y nutricion: Organo de la Sociedad Espanola de Endocrinologia y Nutricion 2016; 63: 291-303
    CrossrefPubMedSearch in Google Scholar
  • 14 Anagnostis P, Gkekas NK, Achilla C. et al. Type 2 diabetes mellitus is associated with increased risk of sarcopenia: A systematic review and meta-analysis. Calcif Tissue Int 2020; 107: 453-463
    CrossrefPubMedSearch in Google Scholar
  • 15 Saatmann N, Zaharia OP, Loenneke JP. et al. Effects of blood flow restriction exercise and possible applications in type 2 diabetes. Trends Endocrinol Metab 2021; 32: 106-117
    CrossrefPubMedSearch in Google Scholar
  • 16 Billot M, Calvani R, Urtamo A. et al. Preserving mobility in older adults with physical frailty and sarcopenia: opportunities, Challenges, and recommendations for physical activity interventions. Clin Interv Aging 2020; 15: 1675-1690
    CrossrefPubMedSearch in Google Scholar
  • 17 Zhang X, Zhao Y, Chen S. et al. Anti-diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications. J Cachexia Sarcopenia Muscle 2021; 12: 1368-1379
    CrossrefPubMedSearch in Google Scholar
  • 18 Wu CN, Tien KJ. The impact of antidiabetic agents on sarcopenia in type 2 diabetes: A literature review. J Diabetes Res 2020; 2020: 9368583
    CrossrefPubMedSearch in Google Scholar
  • 19 Bouchi R, Fukuda T, Takeuchi T. et al. Insulin treatment attenuates decline of muscle mass in Japanese patients with type 2 diabetes. Calcif Tissue Int 2017; 101: 1-8
    CrossrefPubMedSearch in Google Scholar
  • 20 Prídavková D, Samoš M, Kazimierová I. et al. Insulin pump therapy - influence on body fat redistribution, skeletal muscle mass and ghrelin, leptin changes in T1D patients. Obes Facts 2018; 11: 454-464
    CrossrefPubMedSearch in Google Scholar
  • 21 Perna S, Guido D, Bologna C. et al. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study. Aging Clin Exp Res 2016; 28: 1251-1257
    CrossrefPubMedSearch in Google Scholar
  • 22 Ida S, Kaneko R, Imataka K. et al. Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus. Curr Diabetes Rev 2021; 17: 293-303
    CrossrefPubMedSearch in Google Scholar
  • 23 McCrimmon RJ, Catarig AM, Frias JP. et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: A substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia 2020; 63: 473-485
    CrossrefPubMedSearch in Google Scholar
  • 24 Liu L, Yan H, Xia M. et al. Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Metab Res Rev 2020; 36: e3292
    CrossrefPubMedSearch in Google Scholar
  • 25 Zeng MD, Fan JG, Lu LG. et al. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis 2008; 9: 108-112
    CrossrefPubMedSearch in Google Scholar
  • 26 Meek SE, Persson M, Ford GC. et al. Differential regulation of amino acid exchange and protein dynamics across splanchnic and skeletal muscle beds by insulin in healthy human subjects. Diabetes 1998; 47: 1824-1835
    CrossrefPubMedSearch in Google Scholar
  • 27 O'Neill BT, Lee KY, Klaus K. et al. Insulin and IGF-1 receptors regulate FoxO-mediated signaling in muscle proteostasis. J Clin Invest 2016; 126: 3433-3446
    CrossrefPubMedSearch in Google Scholar
  • 28 Dutour A, Abdesselam I, Ancel P. et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: A prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab 2016; 18: 882-891
    CrossrefPubMedSearch in Google Scholar
  • 29 Hong Y, Lee JH, Jeong KW. et al. Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy. J Cachexia Sarcopenia Muscle 2019; 10: 903-918
    CrossrefPubMedSearch in Google Scholar